Sweden · Delayed Price · Currency is SEK Corline Biomedical AB Company Description
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden.
The company’s products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting.
It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries.
Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.
| Country | Sweden |
| Founded | 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Henrik Nittmar |
Contact Details
Address: Lefflersgatan 5 Uppsala, 754 50 Sweden | |
| Phone | 46 18 71 30 90 |
| Website | corline.se |
Stock Details
| Ticker Symbol | CLBIO |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0006887451 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Henrik Nittmar Ph.D. | Chief Executive Officer |
| Asa Holm | Chief Operating Officer |